News | Radiation Therapy | February 09, 2016

HPV Status Determines Radiation Resistance of Head and Neck Cancers

UCLA study finds HPV-negative cancer cells are more easily converted into head and neck cancer stem cells than those that are HPV-positive

radiation therapy, head and neck cancers, HPV status, UCLA study

February 9, 2016 — Head and neck cancers that test positive for the herpes papilloma virus (HPV) are known to respond more favorably to radiation therapy than those that test HPV-negative, but an explanation for these differences has remained elusive.

Now, UCLA scientists have shown for the first time that radiation treatment transforms cancer cells into head and neck cancer stem cells — which are known to be resistant to radiation therapy — more effectively when the cancer tests negative for HPV. These findings shed light on why some head and neck cancers fair much worse after radiation therapy despite optimum treatment regimens.

Led by UCLA Jonsson Comprehensive Cancer Center members Erina Vlashi, M.D., and Frank Pajonk, M.D., the study showed the non-stem cancer cells that survived radiation therapy had the ability to convert into cancer stem cells, which have shown to be more resistant to radiation treatment. The process, called “radiation-induced conversion,” happened at a higher frequency in HPV-negative head and neck cancers, providing a clinically relevant explanation for the differences in response to radiation therapy.

The team reviewed 162 head and neck squamous carcinomas (HNSCCs) patients over a two-year period, and confirmed that their outcomes were correlated with their HPV status.

The study was built upon Vlashi and Pajonk’s previous research in breast cancer, which showed that therapy-resistant cancer cells are more prone to therapy-induced conversion depending on the aggressiveness of the type of breast cancer.

While radiation therapy may have some unwanted consequences, it remains an indispensable treatment for people with the disease. Further studies are currently underway to identify drugs that can interfere with radiation-induced conversion, said Vlashi.

The scientists hope this research will lead to a new type of combination treatment to improve the response of head and neck tumor cells to radiation therapy.

The study is available online in the International Journal of Radiation Oncology, Biology and Physics.

For more information: www.redjournal.org

Related Content

CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...
Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones
News | Radiation Therapy | July 05, 2019
Aktina Medical announced that Elekta Instrument AB, based in Sweden, will offer and distribute the Aktina line of...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...